{"id":"https://openalex.org/W7224401294","doi":"https://doi.org/10.1183/13993003.congress-2026.pa2145","title":"Zumilokibart (APG777), a half-life extended monoclonal antibody, improves IL-13\u2013driven airway pathology in preclinical asthma models","display_name":"Zumilokibart (APG777), a half-life extended monoclonal antibody, improves IL-13\u2013driven airway pathology in preclinical asthma models","publication_year":2026,"publication_date":"2026-09-05","ids":{"openalex":"https://openalex.org/W7224401294","doi":"https://doi.org/10.1183/13993003.congress-2026.pa2145"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2026.pa2145","doi":"https://doi.org/10.1183/13993003.congress-2026.pa2145","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2026.pa2145","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway cell biology and immunopathology","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053185546","display_name":"Kristie Barth","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristie Barth","raw_affiliation_strings":["1Apogee Therapeutics, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Boston, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086639071","display_name":"Kimberly A. Barker","orcid":"https://orcid.org/0000-0003-4612-9144","observed_orcids":["https://orcid.org/0000-0003-4612-9144"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly Barker","raw_affiliation_strings":["1Apogee Therapeutics, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Boston, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028211396","display_name":"Nolan Kearns","orcid":"https://orcid.org/0000-0003-3145-0496","observed_orcids":["https://orcid.org/0000-0003-3145-0496"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nolan Kearns","raw_affiliation_strings":["1Apogee Therapeutics, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Boston, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066846450","display_name":"Grant Wickman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Grant Wickman","raw_affiliation_strings":["1Apogee Therapeutics, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Boston, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022827775","display_name":"Lukas Dillinger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lukas Dillinger","raw_affiliation_strings":["1Apogee Therapeutics, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Boston, United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA2145","last_page":"PA2145"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12528","display_name":"IL-33, ST2, and ILC Pathways","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10877","display_name":"Allergic Rhinitis and Sensitization","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/il-13-inhibition","display_name":"IL-13 inhibition","score":0.8299999833106995},{"id":"https://openalex.org/keywords/asthma","display_name":"asthma","score":0.824999988079071},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8169999718666077},{"id":"https://openalex.org/keywords/mucus-production","display_name":"mucus production","score":0.906000018119812},{"id":"https://openalex.org/keywords/airway-eosinophils","display_name":"airway eosinophils","score":0.8309999704360962},{"id":"https://openalex.org/keywords/eotaxin-3","display_name":"eotaxin-3","score":0.906000018119812},{"id":"https://openalex.org/keywords/periostin","display_name":"periostin","score":1.0},{"id":"https://openalex.org/keywords/type-2-inflammation","display_name":"type 2 inflammation","score":0.7889999747276306},{"id":"https://openalex.org/keywords/airway-epithelial-barrier","display_name":"airway epithelial barrier","score":0.6470000147819519},{"id":"https://openalex.org/keywords/soluble-mediators","display_name":"soluble mediators","score":0.7139999866485596}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8328999876976013},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4975000023841858},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.46790000796318054},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.4372999966144562},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3709000051021576},{"id":"https://openalex.org/C105922876","wikidata":"https://www.wikidata.org/wiki/Q1423981","display_name":"Airway","level":2,"score":0.30979999899864197},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.30730000138282776},{"id":"https://openalex.org/C2776178081","wikidata":"https://www.wikidata.org/wiki/Q3286546","display_name":"Respiratory disease","level":3,"score":0.2703999876976013},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.2619999945163727},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.25690001249313354}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2026.pa2145","doi":"https://doi.org/10.1183/13993003.congress-2026.pa2145","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2026.pa2145","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway cell biology and immunopathology","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7165518039","https://openalex.org/W7224445463","https://openalex.org/W2332246009","https://openalex.org/W1982835289","https://openalex.org/W4388676678","https://openalex.org/W2031137924","https://openalex.org/W2119617139","https://openalex.org/W2991678001","https://openalex.org/W3031220426","https://openalex.org/W2321895315"],"abstract_inverted_index":{"Background:":[0],"Interleukin-13":[1],"(IL-13)":[2],"plays":[3],"a":[4,46],"key":[5,182],"role":[6],"in":[7,25,68,79,101,197,211],"asthma":[8,26,154,185],"by":[9],"promoting":[10],"Type":[11,138],"2":[12,139],"inflammation,":[13],"excessive":[14],"mucus":[15,62,88,116,146,164],"production,":[16,63,89,117],"and":[17,33,64,90,118,142,144,166,169,191,206],"eosinophilic":[18,189],"infiltration.":[19],"Anti-IL-13":[20],"therapies":[21],"demonstrated":[22],"inconsistent":[23],"efficacy":[24],"trials,":[27],"possibly":[28],"due":[29],"to":[30],"trial":[31],"design":[32],"suboptimal":[34],"dosing,":[35],"highlighting":[36],"the":[37,55,149],"need":[38],"for":[39,49],"additional":[40],"data":[41,174,203],"around":[42],"IL-13":[43,183],"inhibition":[44],"as":[45],"therapeutic":[47],"strategy":[48],"asthma.":[50,73,215],"Objective:":[51],"This":[52],"study":[53],"evaluated":[54,78],"impact":[56],"of":[57,72,137,209],"zumilokibart":[58,130,156,179,200],"on":[59],"barrier":[60,161],"dysfunction,":[61,115],"soluble":[65,91,119],"mediator":[66,92,120],"release":[67,121],"disease-relevant":[69],"preclinical":[70],"models":[71],"Methods:":[74],"Zumilokibart":[75,96],"activity":[76,97],"was":[77,98],"mice":[80,126],"intranasally":[81],"injected":[82],"with":[83,112,128,199,213],"human":[84,102],"IL-13.":[85,113],"Airway":[86],"eosinophils,":[87],"levels":[93,136],"were":[94,122],"evaluated.":[95,123],"also":[99],"assessed":[100],"airway":[103,132,145,150],"epithelial":[104,151],"air-liquid":[105],"interface":[106],"cultures":[107,152],"from":[108,153],"asthmatic":[109],"donors":[110],"stimulated":[111],"Barrier":[114],"Results:":[124],"In":[125,148],"challenged":[127],"IL-13,":[129],"reduced":[131],"eosinophil":[133],"influx,":[134],"tissue/serum":[135],"mediators":[140],"eotaxin":[141],"periostin,":[143],"production.":[147],"donors,":[155],"blocked":[157],"IL-13-mediated":[158],"effects,":[159],"maintaining":[160],"integrity,":[162],"inhibiting":[163],"generation,":[165],"decreasing":[167],"eotaxin-3":[168],"periostin":[170],"release.":[171],"Conclusions:":[172],"Preclinical":[173],"presented":[175],"here":[176],"demonstrate":[177],"that":[178],"effectively":[180],"targets":[181],"driven":[184],"mechanisms,":[186],"reducing":[187],"mucus,":[188],"infiltration,":[190],"inflammatory":[192],"mediators.":[193],"These":[194],"results":[195],"are":[196],"line":[198],"Phase":[201],"1b":[202],"showing":[204],"rapid":[205],"sustained":[207],"suppression":[208],"FeNO":[210],"patients":[212],"mild-to-moderate":[214]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-30T00:00:00"}